Education
About Us
Working with TipRanks
Follow Us
Oramed Pharmaceuticals (ORMP)
NASDAQ:ORMP
ORMP Stock Chart & Stats
$2.72
-$0.04(-1.65%)
At close: 4:00 PM EST
$2.72
-$0.04(-1.65%)
Day’s Range― - ―
52-Week Range$1.82 - $3.09
Previous CloseN/A
Volume63.61K
Average Volume (3M)210.74K
Market Cap
$113.44M
Enterprise Value-$21.85M
Total Cash (Recent Filing)$97.94M
Total Debt (Recent Filing)$912.00K
Price to Earnings (P/E)2.8
Beta0.53
Next Earnings
Jan 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.13
Shares Outstanding39,802,456
10 Day Avg. Volume339,860
30 Day Avg. Volume210,739
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio-11.72
Enterprise Value/Market Cap-0.19
Enterprise Value/Revenue-10.93
Enterprise Value/Gross Profit455.30
Enterprise Value/Ebitda5.34
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.34
Revenue Forecast (FY)$2.00M
Bulls Say, Bears Say
Bulls Say
InvestmentThe joint venture will receive a significant capital infusion, with HTIT committing a notable $70M investment, supplemented by a $20M investment from Oramed.
Joint VentureOramed entered into a definitive agreement with HTIT, marking a milestone in the creation of a joint venture centered around Oramed’s cutting-edge oral drug delivery technology.
Bears Say
Clinical EfficacyThe candidates in Oramed's pipeline have yet to show definitive clinical proof-of-concept efficacy.
Oramed Pharm News
ORMP FAQ
What was Oramed Pharmaceuticals’s price range in the past 12 months?
Oramed Pharmaceuticals lowest stock price was $1.82 and its highest was $3.09 in the past 12 months.
What is Oramed Pharmaceuticals’s market cap?
Oramed Pharmaceuticals’s market cap is $113.44M.
When is Oramed Pharmaceuticals’s upcoming earnings report date?
Oramed Pharmaceuticals’s upcoming earnings report date is Jan 08, 2026 which is in 34 days.
How were Oramed Pharmaceuticals’s earnings last quarter?
Oramed Pharmaceuticals released its earnings results on Nov 17, 2025. The company reported $1.131 earnings per share for the quarter, beating the consensus estimate of -$0.04 by $1.171.
Is Oramed Pharmaceuticals overvalued?
According to Wall Street analysts Oramed Pharmaceuticals’s price is currently Overvalued.
Does Oramed Pharmaceuticals pay dividends?
Oramed Pharmaceuticals does not currently pay dividends.
What is Oramed Pharmaceuticals’s EPS estimate?
Oramed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oramed Pharmaceuticals have?
Oramed Pharmaceuticals has 39,802,456 shares outstanding.
What happened to Oramed Pharmaceuticals’s price movement after its last earnings report?
Oramed Pharmaceuticals reported an EPS of $1.131 in its last earnings report, beating expectations of -$0.04. Following the earnings report the stock price went up 0.429%.
Which hedge fund is a major shareholder of Oramed Pharmaceuticals?
Currently, no hedge funds are holding shares in ORMP
Oramed Pharm Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.25%
12-Months-Change
Fundamentals
Return on Equity
24.38%
Trailing 12-Months
Asset Growth
33.57%
Trailing 12-Months
Company Description
Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
Technical Analysis
Adverum Biotechnologies
―
Whitehawk Therapeutics
―
Quince Therapeutics
―
ALX Oncology Holdings
―
Spruce Biosciences
―
Ownership Overview
19.29% Insiders
0.29% Mutual Funds
13.79% Other Institutional Investors
65.95% Public Companies and
Individual Investors